Biological Effects of 224Ra: Benefit and Risk of Therapeutic Application Proceedings of the Second Symposium at Neuherberg/München, September 20–21, 1976

Session I.- Zur Klinik der ankylosierenden Spondylitis (Morbus Bechterew).- Pathology and radiology of ankylosing spondylitis.- Session II.- Indication for 224Ra-therapy in ankylosing spondylitis.- Problems and results of a new follow-up study - 224Ra in adult ankylosing spondylitis patients.- Addendum to the previous paper: Risk to bone from present 224Ra therapy.- Quality control in the production process and purity of 224Ra for injection.- Therapeutical results in a follow-up study 224Ra-therapy of ankylosing spondylitis.- X-ray therapy in the treatment of ankylosing spondylitis.- Session III.- Radiosynoviorthesis: Local treatment of rheumatoid arthritis.- Comparison of the efficacy of 224and other radio-isotopes in the treatment of rheumatoid arthritis.- Experimental data on the injection of 224Ra into the knee-joint of rats and rabbits.- Intravenous injection of 224Ra in Morbus Paget.- Session IV.- Clinical experiences concerning late effects and risks of 224Ra.- Osteogenic sarcomas in mice after 224Ra or 226Ra administrations.- Biological effects of 224Ra and 226Ra and their relative radiotoxicity in mice.- The dependence of late effects in mice on the temporal distribution of skeletal ?-doses from 224Ra and 227Th.- Histopathology of early effects of 224Ra on bone tissue.- Expression of type C RNA virus particles in 224Ra-induced osteosarcomas.- Session V.- Bone sarcoma risks to man from 224Ra 226Ra and 239Pu.- Problems in radiological protection involving ?-emitters in bone.- A model for the induction of bone cancer by 224Ra.- Methodological aspect of epidemio-logical inquiries in clinical radio- biology.- Notre experience du 224Ra dans le traitement de la spondylarthrite ankylosante.- Round Table Discussion I Moderator: C.W. Mays Risk evaluation of ankylosingspondylitis therapy.- Round Table Discussion II Moderator: W. Koch Clinical results of ankylosing spondylitis therapy.- R.H. Mole Concluding remarks.- List of participants.